Efficacy and safety of unfractionated heparin versus enoxaparin: A pooled analysis of ASSENT-3 and -3 PLUS data

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 10, 2006, Pages 1421-1426

  Armstrong, Paul W ^a   Chang, Wei Ching ^a   Wallentin, Lars ^b   Goldstein, Patrick ^c   Granger, Christopher B ^e   Bogaerts, Kris ^f   Danays, Thierry ^d   Van De Werf, Frans ^f  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIV LILLE   (France)

^d BOEHRINGER INGELHEIM   (France)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; REVASCULARIZATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 33646778830     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051410     Document Type: Article

References (13)

1. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605-13.
2. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-42.
3. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
4. Herlitz J, Karlson BW, Bang A, et al. Characteristics and outcome for patients with acute chest pain in relation to whether or not they were transported by ambulance. Eur J Emerg Med 2000;7:195-200.
5. Canto JG, Zalenski RI, Ornato JP, et al. for the National Registry of Myocardial Infarction 2 Investigators. Use of emergency medical services in acute myocardial infarction and subsequent quality of care. Observations from the National Registry of Myocardial Infarction 2. Circulation 2002;106:3018-23.
6. Widimsk P, Budesinsky T, Vorac D, et al.: PRAGUE Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003;24:94-104.
7. Andersen HR, Nielsen T, Rasmussen K, et al. for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-42.
8. Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-30.
9. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 1999;354:716-22.
10. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
11. Pieper KS, Tsiatis AA, Davidian M, et al. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: Exploration of methods. Circulation 2004;109:641-6.
12. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342(8886-7):1523-8.
13. Antman EM, Morrow DA, McCabe CH, et al; for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. New Engl J Med 2006;354(14):1477-88.